Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

884 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome of COVID-19 in Patients With Mantle Cell Lymphoma-Report From the European MCL Registry.
Tilch MK, Visco C, Kinda S, Hermine O, Kohn M, Besson C, Lamure S, Duléry R, Ragaini S, Eyre TA, Van Meerten T, Ohler A, Eckerle S, Dreyling M, Hess G, Giné E, Gomes da Silva M. Tilch MK, et al. Among authors: hess g. Hemasphere. 2022 Apr 8;6(5):e0711. doi: 10.1097/HS9.0000000000000711. eCollection 2022 May. Hemasphere. 2022. PMID: 35425889 Free PMC article.
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R, Hess G, Köppler H, Heymanns J, Thomalla J, Aldaoud A, Losem C, Schmitz S, Haak U, Huber C, Unterhalt M, Hiddemann W, Dreyling M; German Low Grade Lymphoma Study Group. Weide R, et al. Among authors: hess g. Leuk Lymphoma. 2007 Jul;48(7):1299-306. doi: 10.1080/10428190701361828. Leuk Lymphoma. 2007. PMID: 17613757 Clinical Trial.
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network.
Dreyling M, Kluin-Nelemans HC, Beà S, Hartmann E, Salaverria I, Hutter G, Perez-Galan P, Roue G, Pott C, Le Gouill S, Cortelazzo S, Rule S, Hess G, Zaja F, Vitolo U, Szymczyk M, Walewski J, Ribrag V, Unterhalt M, Hermine O, Hoster E; European Mantle Cell Lymphoma Network. Dreyling M, et al. Among authors: hess g. Leuk Lymphoma. 2011 Dec;52(12):2226-36. doi: 10.3109/10428194.2011.600488. Epub 2011 Aug 18. Leuk Lymphoma. 2011. PMID: 21851218 Review.
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network.
Dreyling M, Kluin-Nelemans HC, Beà S, Klapper W, Vogt N, Delfau-Larue MH, Hutter G, Cheah C, Chiappella A, Cortelazzo S, Pott C, Hess G, Visco C, Vitolo U, Klener P, Aurer I, Unterhalt M, Ribrag V, Hoster E, Hermine O; European MCL Network. Dreyling M, et al. Among authors: hess g. Leuk Lymphoma. 2013 Apr;54(4):699-707. doi: 10.3109/10428194.2012.733882. Epub 2012 Nov 21. Leuk Lymphoma. 2013. PMID: 23020649 Review.
Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation.
Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, Elter T, von Bubnoff N, Dreyling M, Ringhoffer M, Krause SW, Derigs G, Klimm B, Niemann D, Fritsch K, Finke J, Illerhaus G. Schorb E, et al. Among authors: hess g. Haematologica. 2013 May;98(5):765-70. doi: 10.3324/haematol.2012.076075. Epub 2013 Jan 8. Haematologica. 2013. PMID: 23300179 Free PMC article.
A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
Witzens-Harig M, Memmer ML, Dreyling M, Hess G. Witzens-Harig M, et al. Among authors: hess g. BMC Cancer. 2013 Jun 25;13:308. doi: 10.1186/1471-2407-13-308. BMC Cancer. 2013. PMID: 23799873 Free PMC article. Clinical Trial.
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Dreyling M, et al. Among authors: hess g. Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7. Lancet. 2016. PMID: 26673811 Clinical Trial.
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
Hess G, Rule S, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Caballero D, Joao C, Witzens-Harig M, Bence-Bruckler I, Cho SG, Zhou W, Goldberg JD, Trambitas C, Enny C, Vermeulen J, Traina S, Chiou CF, Diels J, Dreyling M. Hess G, et al. Leuk Lymphoma. 2017 Dec;58(12):2824-2832. doi: 10.1080/10428194.2017.1326034. Epub 2017 May 30. Leuk Lymphoma. 2017. PMID: 28556689 Clinical Trial.
884 results